Business Context and Reporting Period
Company: Marker Therapeutics, Inc. (MRKR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: A clinical-stage immuno-oncology company developing non-engineered, multi-antigen recognizing (MAR) T cell therapies for hematological malignancies and solid tumors. The company relies on third-party manufacturing following the sale of its in-house facility in 2023.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $349,104 | $1,244,061 |
| Net Loss | $(4,446,184) | $(2,392,822) |
| Loss Per Share (Basic/Diluted) | $(0.40) | $(0.27) |
| Operating Expenses | $4,957,777 | $3,793,078 |
| Cash and Cash Equivalents (End of Period) | $13,693,208 | $11,323,428 |
| Working Capital | $14,491,871 | $11,788,234 |
| Net Cash Used in Operating Activities | $(5,499,737) | $(3,837,118) |
Debt and Liquidity: The company has no long-term debt listed on the balance sheet. Current liabilities total $2.5 million, primarily accounts payable and a related party payable. As of March 31, 2025, the company held approximately $13.7 million in cash and cash equivalents.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 72% to $349,104, driven by a reduction in grant income recognition compared to the prior year.
- Increased Operating Loss: Net loss widened by 86% to $4.4 million. This was primarily due to a 31% increase in operating expenses.
- Vendor Termination Cost: A one-time loss of $453,135 was recorded for the early termination of a Master Services Agreement (MSA) with Cell Ready, LLC, a related party.
- R&D Expenses: Research and development expenses increased by 22% ($560,000) due to higher clinical trial and process development costs, partially offset by reduced outsourced manufacturing costs.
- Stock-Based Compensation: Increased significantly to $379,144 (from $79,417 in Q1 2024), largely due to the acceleration of unvested options for consultants.
Guidance, Outlook, and Risks
- Going Concern Warning: Management has raised substantial doubt regarding the company's ability to continue as a going concern. Based on current cash levels and burn rate, the company anticipates funding operations only into the first quarter of 2026, assuming no additional grant funds are received.
- Capital Strategy: The company plans to raise additional capital through equity issuances and grant applications. A new At-The-Market (ATM) offering agreement with H.C. Wainwright & Co. LLC allows for up to $11.4 million in sales.
- Manufacturing Transition: Following the termination of the MSA with Cell Ready, the company is evaluating and qualifying new third-party manufacturing partners to support a pivotal lymphoma trial expected in 2026.
- Clinical Progress: The Phase 1 APOLLO study for MT-601 (lymphoma) reported early objective responses in 78% of patients with no dose-limiting toxicities. The company is advancing MT-601 for pancreatic cancer and MT-401-OTS for AML.
- Grant Receivables: Significant grant income is recorded as receivables ($2.4 million total), including $2.3 million from CPRIT, which represents earned income not yet received in cash.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2026" liquidity projection given the high cash burn rate of ~$5.5 million per quarter.
- Grant Collections: Confirm the timing of cash receipts for the $2.4 million in grant receivables, particularly the CPRIT AML and Pancreatic grants.
- Manufacturing Supply Chain: Assess the status of qualifying new CDMO partners to ensure no disruption to the 2026 pivotal trial.
- Dilution Risk: Review the impact of the outstanding 7.8 million warrants (including 5 million private placement warrants) on future share count upon exercise.
- Related Party Transactions: Monitor future expenses related to Baylor College of Medicine and Wilson Wolf Manufacturing, which accounted for $1.7 million in related party expenses in Q1 2025.